Bluejay Diagnostics, Inc.

BJDX

Healthcare Medical Devices

Bluejay Diagnostics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $249,000.00.

EPS
+80.1%
Free cash flow
+20.1%

Quarter to June 2026, against a year earlier

2.35 0.16 +7.31%
Market cap
$2.6M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
0.8×
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
4.64 2.81 4.88 2.92
Net Debt/EBITDA
4.18 1.95 3.66 1.94
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.79) (1.63) (3.63) (3.45)
Book value per Share
4.53 4.25 13.31 9.38
Free Cash Flow
(1.64) (1.60) (1.63) (1.36)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026